The Biospecimen and Pathology Core (Core B) is crucial for all Penn/Wistar SPORE in Skin Cancer activities. It fully utilizes the infrastructures at the Penn/Wistar and addresses research needs for melanoma patient biospecimens of all the SPORE projects that are not met by current shared facilities at these institutions. Standardized procedures for procurement, processing, storage, quality control, histopathologic evaluation and distribution of samples will ensure optimal utilization and distribution of limited tissue samples according to the guidelines established by the Tissue and Resource Allocation Committee. In addition to collecting, storing and distributing a wide range of biospecimens, the Core maintains a comprehensive tissue database (Labvantage LIMS database) that includes detailed pathologic characteristics and essential clinical data including family history, current therapies of patients, tissue type, amount of stored tissue, distribution log associated with each collected specimen (tissue or blood), and results of molecular (or other analytic) studies generated from these biospecimens. The close relationship with the Biostatistics Core will allow for efficient analysis of the data produced by the different SPORE projects. Leadership for the Core will be shared by a senior dermatopathologist with expertise in melanoma diagnosis and translational research, including histopathologic evaluation, molecular analysis and quality-control procedures as well as a senior pathologist with expertise in tissue collection, database design and bioinformatics. The core interacts extensively with investigators in each project, and shared facilities of the Penn/Wistar Cancer Centers. The services of the Core B enhance the efficient operation of the translational studies by SPORE investigators in a cost-effective manner, and expedite the application of discoveries at the bench to clinical practice, and clinical results to basic research.

Public Health Relevance

The Biospecimen and Pathology Core is a required Core that serves the Penn/Wistar SPORE in Skin Cancer by providing well annotated high quality biospecimens. The Core will function as a hub to procure, process, track, store and distribute well annotated biospecimens including quality controls.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA174523-05
Application #
9542740
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Sarvi, Sana; Crispin, Richard; Lu, Yuting et al. (2018) ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells. Cell Chem Biol 25:1456-1469.e6
Noguera-Ortega, Estela; Amaravadi, Ravi K (2018) Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role? Cancer Discov 8:266-268
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215
Gangadhar, Tara C; Savitch, Samantha L; Yee, Stephanie S et al. (2018) Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment Cell Melanoma Res 31:73-81
Zhang, Gao; Wu, Lawrence W; Mender, Ilgen et al. (2018) Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res 24:4771-4784
Natale, Christopher A; Li, Jinyang; Zhang, Junqian et al. (2018) Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade. Elife 7:
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32

Showing the most recent 10 out of 89 publications